Taylor S - Search Results

1

A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.

Torok H, Taylor S, Baumann L, Jones T, Wieder J, Lowe N, Jarret M, Rich P, Pariser D, Tschen E, Martin D, Menter A, Weiss J. Torok H, et al. Among authors: taylor s. J Drugs Dermatol. 2005 Sep-Oct;4(5):592-7. J Drugs Dermatol. 2005. PMID: 16167418 Clinical Trial.

2

Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.

Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, Menter A, Baumann L, Wieder JJ, Jarratt MM, Pariser D, Martin D, Weiss J, Shavin J, Ramirez N. Taylor SC, et al. Cutis. 2003 Jul;72(1):67-72. Cutis. 2003. PMID: 12889718 Clinical Trial.

3

Natural considerations for skin of color.

Baumann L, Rodriguez D, Taylor SC, Wu J. Baumann L, et al. Cutis. 2006 Dec;78(6 Suppl):2-19. Cutis. 2006. PMID: 17354519 Review.

4

Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.

Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, Garrett S; Dapsone Gel Long-Term Safety Study Group. Lucky AW, et al. Among authors: taylor s. J Drugs Dermatol. 2007 Oct;6(10):981-7. J Drugs Dermatol. 2007. PMID: 17966175 Clinical Trial.

5

Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.

Piette WW, Taylor S, Pariser D, Jarratt M, Sheth P, Wilson D. Piette WW, et al. Among authors: taylor s. Arch Dermatol. 2008 Dec;144(12):1564-70. doi: 10.1001/archdermatol.2008.518. Arch Dermatol. 2008. PMID: 19075138 Clinical Trial.

6

Current Understanding of Seborrheic Keratosis: Prevalence, Etiology, Clinical Presentation, Diagnosis, and Management.

Jackson JM, Alexis A, Berman B, Berson DS, Taylor S, Weiss JS. Jackson JM, et al. Among authors: taylor s. J Drugs Dermatol. 2015 Oct;14(10):1119-25. J Drugs Dermatol. 2015. PMID: 26461823

7

Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.

Taylor SC, Cook-Bolden FE, McMichael A, Downie JB, Rodriguez DA, Alexis AF, Callender VD, Alvandi N. Taylor SC, et al. J Drugs Dermatol. 2018 Feb 1;17(2):160-167. J Drugs Dermatol. 2018. PMID: 29462223 Clinical Trial.

8

Best practices in the treatment of melasma with a focus on patients with skin of color.

Desai SR, Alexis AF, Elbuluk N, Grimes PE, Weiss J, Hamzavi IH, Taylor SC. Desai SR, et al. J Am Acad Dermatol. 2024 Feb;90(2):269-279. doi: 10.1016/j.jaad.2023.07.1045. Epub 2023 Sep 23. J Am Acad Dermatol. 2024. PMID: 37748556

9

Safety of nonanimal stabilized hyaluronic acid dermal fillers in patients with skin of color: a randomized, evaluator-blinded comparative trial.

Taylor SC, Burgess CM, Callender VD. Taylor SC, et al. Dermatol Surg. 2009 Oct;35 Suppl 2:1653-60. doi: 10.1111/j.1524-4725.2009.01344.x. Dermatol Surg. 2009. PMID: 19807760 Clinical Trial.

10

Fillers in the skin of color population.

Heath CR, Taylor SC. Heath CR, et al. J Drugs Dermatol. 2011 May;10(5):494-8. J Drugs Dermatol. 2011. PMID: 21533295

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,595 results

Search Page

Filters